All Insights White Paper Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

    Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

    Patient Centricity

    Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

    This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions through DPS laws that have to be later reversed in generic-to-branded drug switch-backs for some patients

    Download White Paper
    Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

    The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in generic-to-branded drug switch-backs for some patients.  This paper also demonstrates another application of longitudinal prescription patient-level data to show how brand-to-generic substitution (especially therapeutic substitution) may produce unintended effects that are in not the best interest for some patients as measured by the rate of generic-to-branded drug switch-backs.

    Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Trending insights

    DPS Laws on Brand-Generic Drug Utilization White Paper

    Blog

    How Will The COVID-19 Induced Recession Affect State Medicaid Drug Utilization

    DPS Laws on Brand-Generic Drug Utilization White Paper

    White Paper

    Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?